Clinical Discovery



Clinical Discovery Program


The purpose of the Clinical Discovery Program is to rapidly translate and test novel diagnostic and therapeutic approaches from bench to bedside. This Program focuses primarily on technologies previously developed at CSB but also applies other new technologies as they are related to human biology. The primary fields of interest are currently in cancer dx, clinical imaging and systems analyses. Investigators in this program are practicing clinician scientists from Massachusetts General Hospital and collaborators from other Harvard Medical School teaching hospitals. The program is primarily funded through grants from NIH.

Recent Publications (more...)

Carlson JCT, Hogan C, Ivkovic A
Case 5-2019: A Woman with Delusional Thinking and Paresthesia of the Right Hand. Reply.
N Engl J Med. 2019;380(21):2082 - PMID: 31116941 - DOI: 10.1056/NEJMc1903635
Hogan C, Little BP, Carlson JCT, Freudenreich O, Ivkovic A, Baron JM
Case 5-2019: A 48-Year-Old Woman with Delusional Thinking and Paresthesia of the Right Hand.
N Engl J Med. 2019;380(7):665-674 - PMID: 30763197 - DOI: 10.1056/NEJMcpc1807495
Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Gynecol Oncol. 2019;153(2):223-229 - PMID: 30765148 - DOI: 10.1016/j.ygyno.2019.02.004